TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06404281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T-PD-1 Ab cells
Description: Cells will be extracted from a healthy donor, followed by ex-vivo expansion, activation and genetic engineering. The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.
Study: NCT06390358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tefillin
Description: Wrapping of arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tefillin
Description: Wrapping of arm
Study: NCT05543616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose
Description: injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose
Description: injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose
Description: injection in the muscle
Study: NCT06111014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latozinemab
Description: All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
Study: NCT05183841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator (Ipratropium and Fenoterol)
Description: 8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
Study: NCT05073302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of Nylon catheter (Device-less sentinel unit)
Description: Implantation of the Device-Less sentinel units. Ultrasound monitoring will be performed after Device-Less implantation. Standard Islet cell Transplantation: Will occur simultaneously Portal islet transplantation and subcutaneous islet transplantation in the Device-Less sentinel spaces.~Islets are maintained for a minimum of 6 hours up to 72 hours in supplemented CMRL1066-based media until the time of transplant.~Concomitant to portal vein infusion, islet transplantation will occur in all four (4) DL sentinel spaces.~To explant a unit, the Surgeon will make an incision and then carefully dissect the tissue engrafted around the transplant. The entire transplant site and any adherent tissue capsule can then be removed entirely from the pocket.
Study: NCT06127004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Negative Symptoms (MCT)
Description: See arm/group descriptions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counselling
Description: Se arm/group descriptions
Study: NCT05500872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-education and blood flow restriction training
Description: Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-education
Description: Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
Study: NCT05183841

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 puffs of placebo via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
Study: NCT05346484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-hNIS
Description: CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-hNIS
Description: CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-hNIS
Description: CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-hNIS
Description: CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
Study: NCT06540599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic
Description: comparing the effectiveness of analgesics in endometrial biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic
Description: comparing the effectiveness of analgesics in endometrial biopsy
Study: NCT04748354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: An individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Clinical care provided by a geriatrician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Clinical care provided by a geriatrician.
Study: NCT04941300

Intervention type: OTHER
Group type: OTHER
Intervention: Mailed FIT Outreach
Description: We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized navigation
Description: The standardized navigation includes, but is not limited to, the following key components:~1. Identification of individuals with abnormal FIT~2. Results review and colonoscopy order by provider~3. Results reporting to patient~4. Insurance approval for colonoscopy~5. Colonoscopy scheduling~6. Bowel preparation \& colonoscopy completion~7. Colonoscopy results provided to patient and CHC~8. Referral-to-Care for patients with CRC (if necessary)
Study: NCT05727592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Althernanthera Sissoo
Description: 15g of Althernanthera Sissoo consumed with lunch or dinner per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Consultation
Description: Dietary consultation to improve the intakes of vegetables daily
Study: NCT06542211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention plan for improving ankle dorsiflexion limitation group (experimental group)
Description: The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plantar fasciitis routine rehabilitation group
Description: The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
Study: NCT04794400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen mask
Description: All patients fulfilling inclusion criteria would be offered to test the intervention as part of their care. The intervention consisted only of a standardised way to evaluate this new clinical routine.
Study: NCT04514328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebral 18F-FDG PET-CT
Description: cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)
Study: NCT04745325

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMAART Canada smartphone app
Description: a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMAART Canada smartphone app
Description: a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
Study: NCT05129592

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coherent corrective messages
Description: Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coherent corrective messages
Description: Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coherent corrective messages
Description: Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
Study: NCT05871281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Description: Pelvic floor muscle exercises were performed from different body positions. Duration of interventions - 4 weeks. Frequency - 2 times per week, number of individual contact sessions - 8 .
Study: NCT06282666

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lovett test
Description: A physiotherapist will use the six-grade Lovett scale to measure muscle strength, in which 0 denotes no muscle contractility, and 5 denotes the complete range of motion against gravity, with full resistance. We will test this before the surgery, 24 and 48 hours after the operation.
Study: NCT05871281

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercises
Description: Pelvic floor muscle exercises were performed from different body positions. Duration of interventions - 4 weeks. Frequency - 2 times per week, number of individual contact sessions - 8 .
Study: NCT05821933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 plus Furmonertinib and/or Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 plus Furmonertinib and/or Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 plus Furmonertinib and/or Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 plus Furmonertinib and/or Toripalimab
Study: NCT05129592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coherent corrective messages
Description: Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
Study: NCT05602168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental:Acute leukemia/myelodysplastic or myeloproliferative disease
Description: blood sampling, bone marrow aspirate and buccal swab
Study: NCT06287385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goat-milk Based Formula
Description: Provided Goat-milk Based Formula for babies 1-2 years old
Study: NCT05232383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polychromatic light
Description: Application of polychromatic light at different times of day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polychromatic light
Description: Application of polychromatic light for 2h30 at different times of day with sleep

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red light
Description: Application of red light at different times of day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red light
Description: Application of red light at different times of day with sleep

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: green light
Description: Application of green light at different times of day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: green light
Description: Application of green light at different times of day with sleep
Study: NCT04958434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST005
Description: TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST005
Description: TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
Study: NCT06187155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INR self-management
Description: will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.
Study: NCT05911191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise based prehabilitation
Description: A peripheral muscle strengthening program
Study: NCT05256355

Intervention type: OTHER
Group type: OTHER
Intervention: musculoskeletal ultrasound
Description: The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.

Intervention type: OTHER
Group type: OTHER
Intervention: musculoskeletal ultrasound
Description: The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.

Intervention type: OTHER
Group type: OTHER
Intervention: musculoskeletal ultrasound
Description: The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
Study: NCT06282666

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lovett test
Description: A physiotherapist will use the six-grade Lovett scale to measure muscle strength, in which 0 denotes no muscle contractility, and 5 denotes the complete range of motion against gravity, with full resistance. We will test this before the surgery, 24 and 48 hours after the operation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual analog scale
Description: Investigators will measure pain intensity with VAS (0-10; 0 denotes no pain, 10 maximal pain) before and after the surgery. Pain will be evaluated at rest and upon the activity.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual analog scale
Description: Investigators will measure pain intensity with VAS (0-10; 0 denotes no pain, 10 maximal pain) before and after the surgery. Pain will be evaluated at rest and upon the activity.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quality of Recovery 40
Description: Investigators will assess the quality of recovery with QoR-40 a day after the surgery, a month, and three months following the procedure. The minimal score is 40, and the maximal is 200. The higher the result, the better the quality of recovery is.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quality of Recovery 40
Description: Investigators will assess the quality of recovery with QoR-40 a day after the surgery, a month, and three months following the procedure. The minimal score is 40, and the maximal is 200. The higher the result, the better the quality of recovery is.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ability to sit, stand upright, and walk
Description: A physiotherapist will evaluate the patient's ability to sit, stand upright, and walk at planned times.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ability to sit, stand upright, and walk
Description: A physiotherapist will evaluate the patient's ability to sit, stand upright, and walk at planned times.
Study: NCT05160727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg ivgtt d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Concurrent Chemoradiotherapy:~Irinotecan: 80mg/m2/w (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2/w (UGT1A1\*28 and \*6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1\*28 and \*6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy
Study: NCT05806762

Intervention type: DEVICE
Intervention: BioIntellisense
Description: Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.
Study: NCT04393701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional blood sampling
Description: Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program
Study: NCT06164912

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Simulation with Pseudofeedback
Description: Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Simulation with Neurofeedback
Description: Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
Study: NCT05005611

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pack of powder without probiotics.~1 pack / day
Study: NCT04985942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily.
Study: NCT04922788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanocovax
Description: Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,5 mg Aluminum adjuvant
Study: NCT05478486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSP008-22
Description: It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort.
Study: NCT05005611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics Lactobacillus salivarius AP-32
Description: A pack of powder with probiotics Lactobacillus salivarius AP-32~1 pack / day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics Bifidobacterium animalis subsp. lactis CP-9
Description: A pack of powder with probiotics Bifidobacterium animalis subsp. lactis CP-9~1 pack / day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics Lactobacillus rhamnosus LGG
Description: A pack of powder with probiotics Lactobacillus rhamnosus LGG~1 pack / day